Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120

AIDS Research and Human Retroviruses

Volumn 16, Issue 8, 2000, Pages 741-749

  Rizzuto, Carlo ^a,b   Sodroski, Joseph ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 120;

ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN TERTIARY STRUCTURE; REACTION ANALYSIS; RECEPTOR BINDING; SITE DIRECTED MUTAGENESIS; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; BINDING SITES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; RECEPTORS, CCR5;

EID: 0034690683     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200308747     Document Type: Article

References (87)

1. 1. Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, and Montagnier L: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-871.
2. 2. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, Palker TJ, Redfield R, Oleske J, Safai B, et al.: Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984; 224:500-503.
3. 3. Kanki PJ, Barin F, M'Boup S, Allan JS, Romet-Lemonne JL, Marlink R, McLane MF, Lee TH, Arbeille B, Denis F, et al.: New human T-lymphotropic retrovirus related to simian T-lymphotropic virus type III (STLV-IIIAGM). Science 1986;232:238-243.
4. 4. Letvin NL, Daniel MD, Sehgal PK, Desrosiers RC, Hunt RD, Waldron LM, MacKey JJ, Schmidt DK, Chalifoux LV, and King NW: Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science 1985;230:71-73.
5. 5. Daniel MD, Letvin NL, King NW, Kannagi M, Sehgal PK, Hunt RD, Kanki PJ, Essex M, and Desrosiers RC: Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 1985;228: 1201-1204.
6. 6. Clavel F, Guetard D, Brun-Vezinet F, Chamaret S, Rey MA, Santos-Ferreira MO, Laurent AG, Dauguet C, Katlama C, Rouzioux C, et al.: Isolation of a new human retrovirus from West African patients with AIDS. Science 1986;233:343-346.
7. 7. Freed EO and Martin MA: The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J Biol Chem 1995;270:23883-23886.
8. 8. Wyatt R and Sodroski J: The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 1998;280:1884-1888.
9. 9. Moore JP and Sodroski J: Antibody cross-competition analysis of the human immunodefiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 1996;70:1863-1872.
10. 10. Moore JP, Sattentau QJ, Wyatt R, and Sodroski J: Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with apanel of monoclonal antibodies. J Virol 1994;68:469-484.
11. 11. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, and Weiss RA: The CD4 (T4) antigen is an essential componet of the receptor for the AIDS retrovirus. Nature (London) 1984;312:763-767.
12. 12. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, Gluckman JC, and Montagnier L: T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (London) 1984;312:767-768.
13. 13. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, and Axel R: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986;47: 333-348.
14. 14. McDougal JS, Kennedy MS, Sligh JM, Cort SP, Mawle A, and Nicholson JK: Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. Science 1986;231:382-385.
15. 15. Clapham PR, McKnight A, and Weiss RA: Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: Induction and enhancement by soluble CD4. J Virol 1992;66:3531-3537.
16. 16. Dumonceaux J, Nisole S, Chanel C, Quivet L, Amara A, Baleux F, Briand P, and Hazan U: Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype. J Virol 1998;72:512-519.
17. 17. Endres MJ, Clapham PR, Marsh M, Ahuja M, Turner JD, Mc Knight A, Thomas JF, Stoebenau-Haggarty B, Choe S, Vance PJ, Wells TN, Power CA, Sutterwala SS, Doms RW, Landau NR, and Hoxie JA: CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 1996;87:745-756.
18. 18. Potempa S, Picard L, Reeves JD, Wilkinson D, Weiss RA, and Talbot SJ: CD4-independent infection by human immunodeficiency virus type 2 strain ROD/B: The role of the N-terminal domain of CXCR-4 in fusion and entry. J Virol 1997;71:4419-4424.
19. 19. Reeves JD, McKnight A, Potempa S, Simmons G, Gray PW, Power CA, Wells T, Weiss RA, and Talbot SJ: CD4-independent infection by HIV-2 (ROD/B): Use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry. Virology 1997;231:130-134.
20. 20. Edinger AL, Mankowski JL, Doranz BJ, Margulies BJ, Lee B, Rucker J, Sharron M, Hoffman TL, Berson JF, Zink MC, Hirsch VM, Clements JE, and Doms RW: CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain. Proc Natl Acad Sci USA 1977;94:14742-14747.
21. 21. Kang CY, Hariharan K, Posner MR, and Nara P: Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120. J Immunol 1993;151:449-457.
22. 22. McKeating JA, Cordell J, Dean CJ, and Balfe P: Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120. Virology 1992;191:732-742.
23. 23. Sattentau QJ and Moore JP: Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 1991;174:407-415.
24. 24. Sattentau QJ, Moore JP, Vignaux F, Traincard F, and Poignard P: Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J Virol 1993;67:7383-7393.
25. 25. Stamatatos L and Cheng-Mayer C: Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. J Virol 1995;69:6191-6198.
26. 26. Thali M, Moore JP, Furman C, Charles M, Ho DD, Robinson J, and Sodroski J: Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993;67:3978-3988.
27. 27. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, and Sodroski J: Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 1995;69:5723-5733.
28. 28. Hill CM, Deng H, Unutmaz D, Kewalramani VN, Bastiani L, Gorny MK, Zolla-Pazner S, and Littman DR: Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. J Virol 1997;71:6296-7304.
29. 29. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C, and Sodroski J: CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (London) 1996;384: 179-183.
30. 30. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, and Moore JP: CD4-dependent, antibody-sensitive interactions between HIV-1 and its coreceptor CCR-5. Nature (London) 1996;384:184-187.
31. 31. Bandres JC, Wang QF, O'Leary J, Baleaux F, Amara A, Hoxie JA, Zolla-Pazner S, and Gorny MK: Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation. J Virol 1998;72:2500-2504.
32. 2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies. Virology 1998;248:394-405.
33. 33. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, and Berger EA: CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-1958.
34. 34. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, and Landau NR: Identification of a major co-receptor for primary isolates of HIV-1. Nature (London) 1996; 381:661-666. [See comments].
35. 35. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, and Sodroski J: The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-1148.
36. 36. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, and Doms RW: A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85: 1149-1158.
37. 37. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, and Paxton WA: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (London) 1996;381:667-673.
38. 38. Doms RW, Edinger AL, and Moore JP: Coreceptor use by primate lentiviruses. In: Human Retroviruses and AIDS 1998: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences (Korber B, Foley BT, Kuiken CL, Rock KA, Calef CE, Gaschen BK, Thakallapally R, Vasil S, Pillai S, and Doddi V, eds.). Los Alamos National Laboratory, Los Alamos, New Mexico, 1998.
39. 39. Feng Y, Broder CC, Kennedy PE, and Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877.
40. 40. Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, Albert J, Scarlatti G, Littman DR, and Fenyö EM: Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997;71:7478-7487.
41. 41. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, Malnati MS, Plebani A, Siccardi AG, Littman DR, Fenyö EM, and Lusso P: In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nature Med 1997;3:1259-1265.
42. 42. Xiao L, Rudolph DL, Owen SM, Spira TJ, and Lal RB: Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. AIDS 1998;12: F137-F143.
43. 43. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR: Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185: 621-628.
44. 44. Chan DC and Kim PS: HIV entry and its inhibition. Cell 1998; 93:681-684.
45. 45. Berson JF and Doms RW: Structure-function studies of the HIV-1 coreceptors. Semin Immunol 1998;10:237-248.
46. 46. Choe H, Martin KA, Farzan M, Sodroski J, Gerard NP, and Gerard C: Structural interactions between chemokine receptors, gp120 Env and CD4. Semin Immunol 1998;10:249-257.
47. 47. Atchison RE, Gosling J, Monteclaro FS, Franci C, Digilio L, Charo IF, and Goldsmith MA: Multiple extracellular elements of CCR5 and HIV-1 entry: Dissociation from response to chemokines. Science 1996;274:1924-1926.
48. 48. Bieniasz PD, Fridell RA, Aramori I, Ferguson SS, Caron MG, and Cullen BR: HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor. EMBO J 1997;16:2599-2609.
49. 49. Doranz BJ, Lu ZH, Rucker J, Zhang TY, Sharron M, Cen YH, Wang ZX, Guo HH, Du JG, Accavitti MA, Doms RW, and Peiper SC: Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J Virol 1997;71:6305-6314.
50. 50. Lu Z, Berson JF, Chen Y, Turner JD, Zhang T, Sharron M, Jenks MH, Wang Z, Kim J, Rucker J, Hoxie JA, Peiper SC, and Doms RW: Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. Proc Natl Acad Sci USA 1997;94:6426-6431.
51. 51. Picard L, Simmons G, Power CA, Meyer A, Weiss RA, and Clapham PR: Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion. J Virol 1997;71:5003-5011.
52. 52. Rucker J, Samson M, Doranz BJ, Libert F, Berson JF, Yi Y, Smyth RJ, Collman RG, Broder CC, Vassart G, Doms RW, and Parmentier M: Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell 1996;87:437-446.
53. 53. Brelot A, Heveker N, Pleskoff O, Sol N, and Alizon M: Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity. J Virol 1997;71: 4744-4751.
54. 54. Picard L, Wilkinson DA, McKnight A, Gray PW, Hoxie JA, Clapham PR, and Weiss RA: Role of the amino-terminal extracellular domain of CXCR-4 in human immunodeficiency virus type 1 entry. Virology 1997;231:105-111.
55. 55. Dragic T, Trkola A, Lin SW, Nagashima KA, Kajumo F, Zhao L, Olson WC, Wu L, Mackay CR, Allaway GP, Sakmar TP, Moore JP, and Maddon PJ: Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol 1998;72:279-285.
56. 56. Farzan M, Choe H, Vaca L, Martin K, Sun Y, Desjardins E, Ruffing N, Wu L, Wyatt R, Gerard N, Gerard C, and Sodroski J: A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol 1998;72:1160-1164.
57. 57. Farzan M, Mirzabekov T, Kolchinsky P, Wyatt R, Cayabyab M, Gerard NP, Gerard C, Sodroski J, and Choe H: Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 1999;96:667-676.
58. 58. Rabut GE, Konner JA, Kajumo F, Moore JP, and Dragic T: Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage-and dualtropic isolates of human immunodeficiency virus type 1. J Virol 1998;72:3464-3468.
59. 59. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, and Sodroski JG: The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (London) 1998;393: 705-711.
60. 60. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, and Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (London) 1998;393:648-659.
61. 61. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, and Lusso P: The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nature Med 1996;2:1244-1247.
62. 62. Xiao L, Owen SM, Goldman I, Lal AA, deJong JJ, Goudsmit J, and Lal RB: CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: Delineation of consensus motif in the V3 domain that predicts CCR-5 usage. Virology 1998;240:83-92.
63. 63. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, and Schuitemaker H: Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66: 3183-3187.
64. 64. Cho MW, Lee MK, Carney MC, Berson JF, Doms RW, and Martin MA: Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J Virol 1998;72:2509-2515.
65. 65. Hoffman TL, Stephens EB, Narayan O, and Doms RW: HIV type I envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors. Proc Natl Acad Sci USA 1998;95: 11360-11365.
66. 66. Ross TM and Cullen BR: The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop. Proc Natl Acad Sci USA 1998;95:7682-7686.
67. 67. Speck RF, Wehrly K, Platt EJ, Atchison RE, Charo IF, Kabat D, Chesebro B, and Goldsmith MA: Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol 1997;71:7136-7139.
68. 68. Wang WK, Dudek T, Zhao YJ, Brumblay HG, Essex M, and Lee TH: CCR5 coreceptor utilization involves a highly conserved arginine residue of HIV type 1 gp120. Proc Natl Acad Sci USA 1998;95:5740-5745.
69. 69. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, and Sodroski J: A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998;280:1949-1953.
70. 70. Wyatt R, Sullivan N, Thali M, Repke H, Ho D, Robinson J, Posner M, and Sodroski J: Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J Virol 1993;67:4557-4565.
71. 71. Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, and Byrn RA: An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J Immunol 1991;146:4325-4332.
72. 72. Gershoni JM, Denisova G, Raviv D, Smorodinsky NI, and Buyaner D: HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex. FASEB J 1993;7:1185-1187.
73. 73. Sullivan N, Sun Y, Sattentau Q, Thali M, Wu D, Denisova G, Gershoni J, Robinson J, Moore J, and Sodroski J: CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: Consequences for virus entry and neutralization. J Virol 1998;72:4694-4703.
74. 74. Korber B, Hahn B, Foley B, Mellors JW, Leitner T, Myers G, McCutchan F, and Kuiken CL (eds.): Human Retroviruses and AIDS 1997: A Compilation of Nucleic Acid and Amino Acid Sequences. Los Alamos National Laboratory, Los Alamos, New Mexico, 1997.
75. 75. Kirchhoff F, Morrison HG, and Desrosiers RC: Identification of V3 mutations that can compensate for inactivating mutations in C4 of simian immunodeficiency virus. Virology 1995;213:179-189.
76. 76. Morrison HG, Kirchhoff F, and Desrosiers RC: Evidence for the cooperation of gp120 amino acids 322 and 448 in SIV mac entry. Virology 1993;195:167-174.
77. 77. Moore JP, Sattentau QJ, Yoshiyama H, Thali M, Charles M, Sullivan N, Poon SW, Fung MS, Traincard F, Pinkus M, et al.: Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: Human immune response to the V1 and V2 domains. J Virol 1993;67:6136-6151.
78. 77a. Myszka D, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, Hendrickson WA, Wyatt R, Sodroski J, and Doyle ML: Energetics of the HIV gp120-CD4 binding reaction. Submitted (2000).
79. 78. Bullough PA, Hughson FM, Skehel JJ, and Wiley DC: Structure of influenza haemagglutinin at the pH of membrane fusion. Nature (London) 1994;371:37-43.
80. 79. Carr CM and Kim PS: A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell 1993;73: 823-832.
81. 80. Chen CH, Matthews TJ, McDanal CB, Bolognesi DP, and Greenberg ML: A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: Implication for viral fusion. J Virol 1995;69: 3771-3777.
82. 81. Jiang S, Lin K, Strick N, and Neurath AR: HIV-1 inhibition by a peptide. Nature (London) 1993;365:113.
83. 82. Jiang S, Lin K, Strick N, and Neurath AR: Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41. Biochem Biophys Res Commun 1993;195:533-538.
84. 83. Chan DC, Fass D, Berger JM, and Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-273.
85. 84. Wild C, Oas T, McDanal C, Bolognesi D, and Matthews T: A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA 1992;89:10537-10541.
86. 85. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, and Wiley DC: Atomic structure of the ectodomain from HIV-1 gp41. Nature (London) 1997;387:426-430.
87. 86. Weissenhorn W, Wharton SA, Calder LJ, Earl PL, Moss B, Aliprandis E, Skehel JJ, and Wiley DC: The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide. EMBO J 1996;15:1507-1514.